Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | PLAU | P00749 | 2/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 4/20 | 0.42 |
| ▸ | CCND1 | P24385 | 4/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.39 |
| ▸ | HTR2C | P28335 | 6/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16370787 | 0.87 | PRKCI (0.55) | PRKCIPLAUPLGBRPF1EGFR | |
| SCHEMBL30672832 | 0.87 | PRKCI (0.55) | PRKCIPLAUPLGBRPF1EGFR | |
| SCHEMBL23413236 | 0.85 | KMO (0.44) | PRKCIBRPF1CDK4CCND1HTR6 | |
| SCHEMBL29780573 | 0.85 | KMO (0.44) | PRKCIBRPF1CDK4CCND1HTR6 | |
| SCHEMBL3650822 | 0.84 | PRKCI (0.59) | PRKCIPLAUPLGBRPF1EGFR | |
| SCHEMBL13836419 | 0.84 | PRKCI (0.55) | PRKCIPLAUPLGBRPF1EGFR | |
| SCHEMBL5089820 | 0.81 | PRKCI (0.56) | PRKCIPLAUPLGBRPF1EGFR | |
| SCHEMBL8959527 | 0.80 | HTR2A (0.59) | PLAUPLGCDK4CCND1LMNA | |
| SCHEMBL21941497 | 0.80 | HTR2A (0.59) | PLAUPLGNTSR1CDK4CCND1 | |
| SCHEMBL8959780 | 0.80 | HTR2C (0.59) | PLAUPLGCDK4CCND1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | PRKCI 1977/4885PLAU 3592/4885PLG 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.